Investigating how immune signals affect allergic asthma
Immune Mediators of IL-22 Signaling Alter Allergic Airway Disease
This study is looking at how certain immune signals, like interleukin-22, affect severe allergic asthma, with the goal of finding new ways to help people who struggle with asthma that doesn't respond well to usual treatments.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pittsburgh at Pittsburgh NIH-funded |
| Lab location | 1 site (Pittsburgh, United States) |
| Project ID | NIH-10808169 on NIH RePORTER |
What this research studies
This research focuses on understanding the role of immune mediators, particularly interleukin-22 (IL-22) and type I interferons, in severe allergic asthma. The study aims to explore how these immune signals contribute to airway inflammation and hyperresponsiveness, which are key features of asthma. By examining the mechanisms that regulate IL-22 and its receptor, the research seeks to identify potential new therapeutic targets for patients suffering from severe, steroid-insensitive asthma. The approach includes modeling the disease and analyzing immune responses in patients to develop more effective treatments.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with severe allergic asthma, particularly those who do not respond well to steroid treatments.
Not a fit: Patients with mild asthma or those whose asthma is well-controlled with standard treatments may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more targeted therapies for patients with severe allergic asthma, improving their quality of life and reducing disease burden.
How similar studies have performed: While the specific focus on IL-22 and type I interferons in severe asthma is relatively novel, previous studies have shown promise in targeting immune pathways for asthma treatment.
Where this research is happening
Pittsburgh, United States
- University of Pittsburgh at Pittsburgh — Pittsburgh, United States (Active)
Researchers
- Principal investigator: Manni, Michelle Lynn — University of Pittsburgh at Pittsburgh
- Study coordinator: Manni, Michelle Lynn
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.